Recruiting Melanoma Studies in Commack
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or met...
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effec...
About Melanoma Clinical Trials in Commack
Melanoma is the most serious type of skin cancer, developing from the pigment-producing cells known as melanocytes. While less common than other skin cancers, melanoma is more likely to spread. Immunotherapy and targeted therapy have revolutionized melanoma treatment.
There are currently 2 melanoma clinical trials recruiting participants in Commack, NY. These studies are seeking a combined 131 participants. Research is being sponsored by Memorial Sloan Kettering Cancer Center. Clinical trial participation is free and participants receive study-related medical care at no cost.
Melanoma Clinical Trials in Commack — FAQ
Are there melanoma clinical trials in Commack?
Yes, there are 2 melanoma clinical trials currently recruiting in Commack, NY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Commack?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Commack research site will contact you about next steps.
Are clinical trials in Commack free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Commack studies also compensate for your time and travel.
What melanoma treatments are being tested?
The 2 active trials in Commack are testing new therapies including novel drugs, biologics, and treatment approaches for melanoma.
Data updated March 2, 2026 from ClinicalTrials.gov